Global Drug Eluting Stents (DES) Market – Industry Trends and Forecast to 2029

Market Analysis and Size

As the healthcare industry reforms to convert the current fee-for-service model to fee-for-value model, intense focus has been placed on the reduction in patient complications, and number and length of hospital stay. Interventional cardiology, in particular, is at a pivot point with remarkable evolution taking place in device technology, operator techniques, and clinical safety and efficacy. Enormous advances have been made in the treatment of coronary artery disease, and the era of 'stent implantation' is upon today’s patients. Moreover, the advent of drug-eluting stents (DES) has considerably changed and revolutionized the interventional landscape, and made angioplasty more predictable, as such, catalyzing the growth of the drug-eluting stents market

• Data Bridge Market Research analyses that the drug eluting stents (DES) market is expected to reach the value of USD 10.22 billion by the year 2029, at a CAGR of 5.42% during the forecast period. On the basis of drug, the sirolimus segment is estimated to expand at a high CAGR during the forecast period. Sirolimus is an extensively used drug for stents. Sirolimus coated drug-eluting stents have less late lumen loss and less angiographic restenosis.

Market Definition

Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages. They are usually used in the treatment of percutaneous coronary intervention or coronary angioplasty. There are two types of drug eluting stents (DES) available, namely, polymer-based coating drug eluting stents (DES) and polymer free coating drug eluting stents (DES).

Drug Eluting Stents (DES) Market Dynamics

Drivers

• Increasing cases of cardiovascular diseases

Cardiovascular disease sometime can be tricky to detect so It is a challenge to and a big problem that the number of cardiovascular disease is growing rapidly with growing population but it is driving the market.

• Rising ageing population

The old and younger population is making a shift as the number of old age people is growing and with that people with disease it also makes it even more hard to treat a patient with old age but it also driving the market.

Additionally, increasing usage of drug eluting stents (DES) for the treatment of atherosclerosis, favourable reimbursement policy, technological advancement and growing popularity of minimally invasive endovascular surgeries  and positively affect the drug eluting stents (DES) market.

Opportunities

Furthermore, rise in prevalence of several cardiovascular diseases such as abnormal heart rhythms, heart attack, heart valve disease, extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Additionally, congenital heart diseases, and heart failure function will further expand the drug eluting stents (DES) market's growth rate in the future. 

Restraints/Challenges

On the other hand, stringent government regulations for product approval, and risk associated with thrombosis and disruption are expected to obstruct market growth. Also, dearth of skilled professionals and strict regulatory approvals are projected to challenge the drug eluting stents (DES) market in the forecast period of 2022-2029.

This drug eluting stents (DES) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug eluting stents (DES) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on Drug Eluting Stents (DES) Market

COVID-19 pandemic has affected every industry worldwide. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, manufacturing and distributing companies of drug-eluting stents have been affected by COVID-19 to a limited extent, owing to shutdowns in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply.

Recent Development

• In February 2019, Medtronic received FDA approval for Resolute DES platforms such as the Resolute Onyx and Resolute Integrity DES, for expanded indications such as de novo chronic total occlusion (CTO)..

Global Drug Eluting Stents (DES) market Scope

The drug eluting stents (DES) market is segmented on the basis of coating, end-users, drug, generation and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Coating

• Polymer based coating
• Biodegradable
• Non-biodegradable
• Polymer free coating
• Microporous surface
• Micro structured surface
• Slotted tubular surface
• Nano porous surface

On the basis of coating, the drug eluting stents (DES) market is segmented into polymer based coating, biodegradable, and non-biodegradable, polymer free coating, microporous surface, microstructured surface, and slotted tubular surface and nanoporous surface.

End use

• Hospitals
• Cardiology centers
• Ambulatory surgical centers

Based on end- users, the drug eluting stents (DES) market is segmented into hospitals, cardiology centers and ambulatory surgical centers.

Drugs

• Sirolimus
• Pactitaxel
• Zotarolimus
• Everolimus
• Biolimus
• Others

On the basis of drugs, the drug eluting stents (DES) market is segmented into sirolimus, pactitaxel, zotarolimus, everolimus, biolimus and others.

Generation

• 1st Generation
• 2nd Generation
• 3RD Generation
• 4TH Generation

Based on generation, the drug eluting stents (DES) market is segmented into 1st Generation, 2nd Generation, 3RD Generation, and 4TH Generation.

Application

• Coronary artery disease
• Peripheral artery disease

The application segment of the drug eluting stents (DES) market is divided into coronary artery disease and peripheral artery disease.

Drug Eluting Stents (DES) Market Regional Analysis/Insights

The drug eluting stents (DES) market is analysed and market size insights and trends are provided by country, coating, end-users, drug, generation and application as referenced above.

The countries covered in the drug eluting stents (DES) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the drug eluting stents (DES) market due to favourable reimbursement policies and strict rules and norms for medical device manufacturing within the region.

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to improvement in healthcare infrastructure and increasing healthcare spending in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The drug eluting stents (DES) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for drug eluting stents (DES) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the drug eluting stents (DES) market. The data is available for historic period 2010-2020.

Competitive Landscape and Drug Eluting Stents (DES) Market Share Analysis

The drug eluting stents (DES) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to drug eluting stents (DES) market.

Some of the major players operating in the drug eluting stents (DES) market are Abbott, B. Braun Melsungen AG, Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, Boston Scientific Corporation, BD, Medtronic, Cook, Merit Medical Systems, Novatech SA, Terumo Corporation, MicroPort Scientific Corporation, Fuji Systems Corp., MICRO-TECH EUROPE, Vascular Concepts, Olympus Corporation, W. L. Gore & Associates Inc., Boston Scientific Corporation, ORBUSNEICH MEDICAL, Relisys Medical Devices Limited, REVA Medical Inc., Sino Medical Sciences Technology Inc., STENTYS SA, HEXACATH and Cardinal Health among others.

SKU-52257